이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Indies Pharma Jamaica 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Guna Muppuri

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO

Guna Muppuri

no data

테뉴어

Dr. Guna Sekhar Muppuri is Founder of Indies Pharma Jamaica Limited and serves as it's Executive Chairman, President and Chief Executive Officer. He is a Medical Doctor by profession and the Founder of th...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Guna Muppuri	Founder	no data	데이터 없음	데이터 없음
Vishnu Muppuri	Co-Founder	no data	데이터 없음	데이터 없음
Lissant Mitchell	Non-Executive Independent Director	3.8yrs	데이터 없음	0.015% JMD 538.0k
Kevin Donaldson	Non Executive Independent Director	3.8yrs	데이터 없음	0.050% JMD 1.8m
Trevor McCartney	Non-Executive Independent Director	no data	데이터 없음	0.015% JMD 538.0k
Dev Singh	Non-Executive Independent Director	5.2yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

경험이 풍부한 이사회: INDIES 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Indies Pharma Jamaica 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Indies Pharma Jamaica Limited, Annual General Meeting, May 29, 2024

Insufficient new directors

Indies Pharma Jamaica Limited Announces Appointment of Directors

Recent updates

Second quarter 2024 earnings released: EPS: JA$0.053 (vs JA$0.02 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Indies Pharma Jamaica Limited, Annual General Meeting, May 29, 2024

First quarter 2024 earnings released: EPS: JA$0.047 (vs JA$0.044 in 1Q 2023)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Full year 2023 earnings released: EPS: JA$0.16 (vs JA$0.17 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: JA$0.06 (vs JA$0.05 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JA$0.02 (vs JA$0.05 in 2Q 2022)

Investor sentiment improves as stock rises 19%

Upcoming dividend of JA$11.33 per share at 3.4% yield

Investor sentiment improves as stock rises 26%

First quarter 2023 earnings released: EPS: JA$0.04 (vs JA$0.04 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: JA$0.05 (vs JA$0.03 in 3Q 2021)

Second quarter 2022 earnings released: EPS: JA$0.05 (vs JA$0.01 in 2Q 2021)

Upcoming dividend of JA$0.11 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS JA$0.01 (vs JA$0.04 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS JA$0.02 (vs JA$0.05 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS JA$0.04 (vs JA$0.03 in 1Q 2020)

Upcoming Dividend of JA$0.11 Per Share

New 90-day high: JA$2.89

Full year 2020 earnings released: EPS JA$0.15 (vs JA$0.12 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: JA$2.31

Full year 2020 earnings released: EPS JA$0.15

New 90-day low: JA$2.43

Indies Pharma Jamaica Limited Announces Appointment of Directors

Third quarter earnings released

CEO

테뉴어

이사회 구성원

평균 재임 기간